FAETH THERAPEUTICS, INC. reports a Return on Equity (ROE) of -96.48%.

What is FTH's dividend yield?

FAETH THERAPEUTICS, INC. offers a dividend yield of 0.00%.

What is FTH's Quality Score?

Our AI rates FTH's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy FTH?

Our AI Timing Score for FTH is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does FTH belong to?

FAETH THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

FTH (NASDAQ) Stock Analysis | FAETH THERAPEUTICS, INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

FTH AI Analysis Summary

Our AI summary for FTH: FAETH THERAPEUTICS, INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -96.48%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

FTH

FAETH THERAPEUTICS, INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 27.24

-1.58 (-5.48%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-96.5%

ROE

-89.8%

ROA

0.00%

Div Yield

FAETH THERAPEUTICS, INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 27.24 Price -1.58 (-5.48%) Day Change	NEWS SCORE: 99

FTH, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	27.24
PBV / Sector	3.89 / 5.20
Earning Per Share	-6.76

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	8.21 M
Average 1W Daily Value	7.64 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

68%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	3,802.47 / 98.71 GREAT
NPM Average (%) / Sector	3,802.47 / -1,721.76 GREAT
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-89.81 / 27.02
ROA Average (%) / Sector	-67.05 / -368.17
ROA Change Average (%) / Sector	23.18 / 5,404.12 GREAT
ROE (%) / Sector	-96.48 / 3.47
ROE Average (%) / Sector	-77.60 / 6.51
ROE Change Average (%) / Sector	22.69 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:52
Symbol	FTH
Name	FAETH THERAPEUTICS, INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	25.78 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	742.94 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1405 Research Boulevard, Rockville, MD, United States, 20850

Phone: 240 243 8000

Website: https://www.faeththerapeutics.com

Sector: Healthcare >> Biotechnology

Description: Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.